Skip to content
NYSE: IGC | Borse Berlin: IGS1.BE | Frankfurt: IGS1
IGC

IGC

India Globalization Capital Inc.

  • Home
  • Life Sciences
  • Infrastructure Business
  • Investors
    • Press Releases
    • SEC Filings
    • XBRL Files
    • Leadership
    • Governance

IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’s Patients

November 23, 2020November 23, 2020 by Alejandro
Posted in News and Filings, Press Releases

Post navigation

← IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients
Annual Report Form 10-K FYE Mar 31, 2020 →

Site Map

  • Home
  • Life Sciences
  • Infrastructure Business
  • Investors
    • Press Releases
    • SEC Filings
    • XBRL Files
    • Leadership
    • Governance

Contact

IGC
Potomac, MD, United States

info@igcinc.us
301-983-0998